Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 10:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 2,516 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sequence Clear all
Withdrawn Phase 1 Interventional

KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer

NCT02205463
View directory record Official record
Conditions
Esophageal Cancer, Stomach Cancer
Interventions
KD019
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2014 · Synced Nov 13, 2026, 10:17 PM EST
Completed Phase 2 Interventional Results available

A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)

NCT06097663
View directory record Official record
Conditions
Coronary Heart Disease, Clonal Hematopoiesis of Indeterminate Potential (CHIP)
Interventions
MAS825, MAS825 Placebo, DFV890, DFV890 placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
St Louis, Missouri • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Nov 13, 2026, 10:17 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability For Palbociclib Formulations

NCT02083640
View directory record Official record
Conditions
Healthy
Interventions
Palbociclib Formulation Reference, Palbociclib Formulation Test
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 4, 2014 · Synced Nov 13, 2026, 10:17 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of PF-06651600 on the Pharmacokinetics of Oral Contraceptive Steroids

NCT04018274
View directory record Official record
Conditions
Healthy
Interventions
PF-06651600, Ethinyl estradiol (EE) and levonorgestrel(LN)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Coral Gables, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Nov 13, 2026, 10:17 PM EST
Completed Phase 4 Interventional Results available

Aspirin Dosing in Diabetic Patients

NCT01201785
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Coronary Artery Disease
Interventions
Aspirin
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Nov 13, 2026, 10:17 PM EST
Recruiting Not applicable Interventional

Using Virtual Reality Technology to Improve Patient Experience and Quality of Care During Brachytherapy

NCT05440760
View directory record Official record
Conditions
Endocervical Cancer
Interventions
The Oculus Quest 2 Virtual Reality Headset
Device
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Nov 13, 2026, 10:17 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult Subjects

NCT02082808
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
DTG, DCV
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Nov 13, 2026, 10:17 PM EST
Completed Not applicable Interventional Results available

High Resolution MRI Study for Prostate Cancer

NCT03292874
View directory record Official record
Conditions
Prostate Cancer
Interventions
high resolution MRI (hrMRI)
Diagnostic Test
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
19 Years and older · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Nov 13, 2026, 10:17 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

NCT05585320
View directory record Official record
Conditions
Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC)
Interventions
IMM-1-104 Monotherapy (Treatment Group A), IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B), IMM-1-104 + modified FOLFIRINOX (Treatment Group C), IMM-1-104 + dabrafenib (Treatment Group D), IMM-1-104 + pembrolizumab (Treatment Group E)
Drug
Lead sponsor
Immuneering Corporation
Industry
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
20
States / cities
Scottsdale, Arizona • Duarte, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 13, 2026, 10:17 PM EST
Completed Not applicable Interventional Results available

Effect of HPIPC for the Treatment of Ischemic Ulcers in Subjects With PAD

NCT01420289
View directory record Official record
Conditions
PVD, Arterial Ulcers
Interventions
High pressure intermittent pneumatic compression (HPIPC), Excercise
Device · Behavioral
Lead sponsor
Calvary Hospital, Bronx, NY
Other
Eligibility
18 Years to 90 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2012 · Synced Nov 13, 2026, 10:17 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Bioequivalence of a New Tapentadol Extended-Release Tablet With Respect to a Tapentadol Extended Release Tablet Under Fasted Conditions in Healthy Subjects

NCT02019485
View directory record Official record
Conditions
Healthy
Interventions
Tapentadol Extended Release (ER) Tamper-Resistant Formulation (TRF), Tapentadol Prolonged-Release Formulation 2 (PR2)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
19 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 24, 2013 · Synced Nov 13, 2026, 10:17 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Diffuse Cutaneous Scleroderma (DSSc) SFDI Study

NCT07090226
View directory record Official record
Conditions
Systemic Scleroderma, Diffuse Cutaneous Scleroderma
Interventions
Spatial-frequency domain imaging (SFDI)
Other
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Nov 13, 2026, 10:17 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose, Pharmacokinetic, Safety, Tolerability and QTc Study of GSK1278863 in Healthy Volunteers

NCT02293148
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863 75 mg, GSK1278863 500 mg, Moxifloxacin 400 mg, Placebo matching GSK1278863, Placebo matching Moxifloxacin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Nov 13, 2026, 10:17 PM EST
Completed Phase 4 Interventional

A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis

NCT02598440
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Alendronate, Ibandronate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Female only
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
54
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tempe, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Nov 13, 2026, 10:17 PM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Home Exercise Program for Women With Infants & Young Children

NCT01738984
View directory record Official record
Conditions
MomZing Exercise Videos Online, Standard Exercise DVD
Interventions
MomZing Web Program, Standard Exercise DVD
Behavioral
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
499 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Apr 12, 2016 · Synced Nov 13, 2026, 10:17 PM EST
Not listed No phase listed Observational Accepts healthy volunteers

Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients

NCT06659458
View directory record Official record
Conditions
Lung Cancer - Non Small Cell, EGFR Exon 19 Deletion Mutation
Interventions
blood draw, Gene sequencing
Other
Lead sponsor
Our Lady of the Lake Hospital
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Nov 13, 2026, 10:17 PM EST
Completed Not applicable Interventional Results available

Improving Adherence to Oral Antipsychotic Medications in People With Schizophrenia

NCT00406718
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Med-eMonitor, PharmCAT, Treatment as Usual
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 60 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Nov 13, 2026, 10:17 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults

NCT05109390
View directory record Official record
Conditions
Healthy
Interventions
Danicopan, Cyclosporine, Tacrolimus, Calcium Carbonate, Aluminum/Magnesium Hydroxide/Simethicone, Omeprazole
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Nov 13, 2026, 10:17 PM EST
Recruiting Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety and Effects of Psychoactive Substances in People With Past Opioid Use

NCT07218549
View directory record Official record
Conditions
Opioid Use, Substance Use Disorders, Opioid Analgesia
Interventions
Placebo, Oxycodone HCl, Kratom 8g, Kratom 12g, Kratom 16g, Kratom 4g
Drug
Lead sponsor
Christopher D. Verrico
Other
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 13, 2026, 10:17 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Transparent Elasticized Adhesive Occlusive Compression Bandage for Use as an Arterial Tourniquet

NCT02592655
View directory record Official record
Conditions
Hemorrhage, Vascular Injury
Interventions
Pneumatic Tourniquet, One Windlass Tourniquet, Two Windlass Tourniquets, Tourniquet Tape 5 cm, Tourniquet Tape 10 cm
Device
Lead sponsor
Marcus Migura
Individual
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Nov 13, 2026, 10:17 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

PPI and Clopidogrel Response

NCT01170533
View directory record Official record
Conditions
Drug Interaction
Interventions
omeprazole and pantoprazole
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Nov 13, 2026, 10:17 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Trial Looking at the Comparability of 2 Different Concentrations of Semaglutide for the 0.5 Milligram (mg) Dose

NCT05689099
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Healthy Participants
Interventions
Semaglutide B, 1.34 mg/mL, Semaglutide B, 0.68 mg/mL
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Nov 13, 2026, 10:17 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Administration in Healthy Subjects

NCT02823171
View directory record Official record
Conditions
Healthy
Interventions
Treatment A: 400 mg Pacritinib P3CT, Treatment B: 400 mg of pacritinib FMI
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Nov 13, 2026, 10:17 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers

Effects of p38 Inhibitor AZD7624 in Corticosteroid Resistant Asthma

NCT02753764
View directory record Official record
Conditions
Corticosteroid Resistant (CR) Asthmatics
Interventions
AZD7624, prednisone, Placebo
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Nov 13, 2026, 10:17 PM EST